)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Antengene Corporation (6996) investor relations material
Antengene Corporation H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary22 Aug, 2025
Executive summary
Achieved key clinical milestones in 2025, including Breakthrough Therapy Designation for ATG-022 (CLDN18.2 ADC) in gastric cancer and expansion of the pipeline in solid tumors and autoimmune diseases.
Revenue for the six months ended June 30, 2025, was RMB53.2 million, down year-over-year but up sequentially, reflecting stabilization after initial NRDL-driven growth.
Loss for the period narrowed significantly to RMB76.4 million from RMB167.0 million year-over-year, with adjusted loss at RMB72.9 million, driven by reduced R&D, selling, and administrative expenses.
Major pipeline progress included new approvals and reimbursement for XPOVIO® (selinexor) in multiple APAC markets and clinical advancements for several assets.
Demonstrated strong efficacy and safety data for lead assets, particularly ATG-022 and ATG-037, with durable responses and favorable safety profiles in difficult-to-treat cancers.
Financial highlights
Revenue: RMB53.2 million (down from RMB60.8 million year-over-year), gross profit: RMB42.9 million, and other income and gains: RMB38.1 million, mainly from increased government grants.
R&D costs: RMB79.9 million (down from RMB130.8 million year-over-year), selling and distribution expenses: RMB37.0 million, administrative expenses: RMB39.3 million.
Loss for the period: RMB76.4 million (down from RMB167.0 million year-over-year); adjusted loss: RMB72.9 million (down from RMB152.6 million year-over-year).
Cash and bank balances: RMB794.1 million as of June 30, 2025.
Targeting over US$5 billion in peak sales for ATG-022 in gastric cancer, not including potential in other CLDN18.2+ tumors.
Outlook and guidance
Ongoing Phase I/II and Phase Ib/II trials for ATG-022 in combination with pembrolizumab and CAPOX in advanced/metastatic gastric cancer, aiming for label expansion.
Continued advancement of 9 clinical stage products across oncology and autoimmune diseases, with focus on expanding commercial team for XPOVIO® launches in APAC.
Ongoing investment in AI-driven R&D and next-generation T-cell engager platform.
IND submissions planned for first-in-class TCEs (ATG-106, ATG-110) in 2027, with continued focus on expanding into new tumor types and autoimmune indications.
Unutilized IPO net proceeds of RMB376.61 million expected to be fully used by end-2026.
XPOVIO revenue outlook post-NRDL normalization?
R&D cost reduction impact on pipeline progress?
How will AI department accelerate TCE pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Antengene Corporation earnings date
H2 202519 Mar, 2026
Next Antengene Corporation earnings date
H2 202519 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Antengene Corporation Limited is a China-based biotechnology company focused on the discovery, development, and commercialization of therapies for cancer and other life-threatening diseases. Antengene's work spans early-stage discovery through clinical development and regulatory approvals, with a focus on targeted therapies and immuno-oncology. It is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage